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Background: Head and neck squamous cell carcinoma (HNSCC) represents one of the most commonly diagnosed
malignancies worldwide. The DDC gene encodes L-DOPA decarboxylase, an enzyme catalyzing the decarboxylation
of L-DOPA to dopamine. We have recently shown that DDC mRNA is a significant predictor of patients’ prognosis in
colorectal adenocarcinoma and prostate cancer. The aim of the current study was to analyze the DDC mRNA
expression in HNSCC patients.
Methods: 53 malignant tumors were resected from the larynx, pharynx, tongue, buccal mucosa, parotid glands,
and nasal cavity, as well as from 34 adjacent non-cancerous tissues of HNSCC patients, and were homogenized.
Total RNA was isolated and converted into first-strand cDNA. An ultrasensitive real-time PCR method based on the
SYBR Green chemistry was used for DDC mRNA quantification in head and neck tissue specimens. Relative
quantification was performed using the comparative Ct (2-ddCt) method.
Results: DDC mRNA levels were lower in squamous cell carcinomas (SCCs) of the larynx and tongue than in
adjacent non-cancerous tissue specimens. Furthermore, low DDC mRNA expression was noticed in laryngeal and
tongue tumors of advanced TNM stage or bigger size, compared to early-stage or smaller tumors, respectively. No
statistically significant differences were observed between SCCs resected from pharynx, buccal mucosa, or nasal
cavity, and their normal counterparts.
Conclusion: This is the first study examining the DDC mRNA expression in HNSCC. According to our results, DDC
mRNA expression may constitute a potential prognostic biomarker in tongue and/or larynx SCCs, which principally
represent the overwhelming majority of HNSCC cases.
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The most usual malignancies developed in the head and
neck area fall into the category of squamous cell carcin-
omas (SCCs) [1]. Head and neck squamous cell carcin-
oma (HNSCC) holds a remarkable position among the
causes leading to death in the developed world [2]. In
particular, this disease is endemic to Southern China and
Southeast Asian countries, whereas its incidence is* Correspondence: ascorilas@biol.uoa.gr
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reproduction in any medium, provided the orsignificantly low in Europe and North America, though
there is evidence of an increasing occurrence even in
these areas [3]. An intermediate incidence has also been
reported in Alaskan Eskimos and the Mediterranean
Basin (North Africa, South Italy, Greece, and Turkey)
[4]. This diversification in the HNSCC incidence among
populations of distinct geographic areas implies a strong
association with genetic and environmental factors [5].
HNSCC includes a great variety of tumors originating
from epithelial cells lining different sites of the head and
neck region. Squamous cell carcinomas arise in nasal
cavity and paranasal sinuses, nasopharynx, hypolarynx,al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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glands, and ear, while miscellaneous tumors such as
neurogenic neoplasms and paragangliomas may also ap-
pear [6]. The molecular basis of HNSCC is very complex
and extremely heterogeneous, exhibiting remarkable dif-
ferences even among people with tumors of the same
type and stage. Research conducted during the last dec-
ade has shed light to the molecular mechanisms under-
lying HNSCC; yet, many essential pieces are still missing
from the puzzle [2]. The discovery and prospective
evaluation of novel molecular biomarkers constitute a
big challenge for the scientific community [7].
The human gene encoding L-DOPA decarboxylase
(DDC) maps to chromosome 7p12.1–12.3, close to the
epidermal growth factor receptor (EGFR) gene, and is
composed of 15 exons spanning a genomic region of
more than 85 kb [8]. Multiple alternatively spliced var-
iants of the DDC gene have been described, with most
of them encoding distinct protein isoforms [9-12]. DDC
is a pyridoxal-phosphate (PLP)-dependent enzyme
catalyzing the decarboxylation of 3,4-dihydroxy-L-
phenylalanine (L-DOPA) to dopamine and 5-hydroxy-L-
tryptophan (5-HTP) to serotonin [13]. DDC is localized
both in the cytosol and cell membrane [14]. Enzymati-
cally active DDC has already been detected in brain,
liver, kidney, adrenal glands, pancreas, cervix [15], pla-
centa [16], as well as in peripheral leukocytes and T-cells
[17]. The presence of DDC activity in leukocytes and in
the histiocytic lymphoma cell line U-937 implies a cross-
talk between the nervous and the immune system, and
raises new questions about the regulatory role of DDC
in immune responses [18,19]. DDC is also a coregulator
of the androgen receptor (AR) in prostate cells. In more
detail, DDC exerts its function in the cytoplasm by en-
hancing the AR activity, and hence modulates the ex-
pression of AR-regulated genes [20,21]. Recently, the
identification and purification of two novel inhibitors of
the enzymatic DDC activity have been reported. One in-
hibitor has been isolated from the human serum and the
other from the membrane fraction of human placental
tissue. [22,23]. Although both inhibitors are believed to
have an endogenous function, their physiological role
remains to be elucidated.
Notably, DDC is regarded as a general biomarker for
neuroendocrine malignancies [24-26]. For instance, ele-
vated DDC mRNA expression has been detected in
small-cell lung carcinoma [27,28] and neuroblastoma
[29]. It has been postulated that DDC mRNA expression
constitutes a biomarker for the detection of minimal re-
sidual disease (MRD) in neuroblastoma patients, as well
as a useful biomarker for the discrimination of neuro-
blastoma from other small round-cell malignancies of
childhood [29,30]. Data from our lab support also the
notion that DDC mRNA expression could be used as anew tissue biomarker in prostate cancer [31], as it can
reliably predict biochemical recurrence and shorter
disease-free survival (DFS) interval in prostate cancer
patients who have previously been subjected to radical
prostatectomy [32]. In addition, Sakakura et al. showed
that DDC is overexpressed in peritoneal dissemination
of gastric carcinoma, and suggested that DDC mRNA
expression is potentially a novel biomarker for the detec-
tion of peritoneal metastases [33].
Interestingly, DDC is implicated in the pathobiology of
prostate cancer, since it promotes abnormal prostate cell
proliferation and neuroendocrine differentiation in an
AR-dependent manner [34]. Moreover, DDC seems to
play a major role in cancer pathobiology and progres-
sion, since it catalyzes the synthesis of biogenic amines
participating in angiogenesis, cell proliferation, and dif-
ferentiation [35,36]. Dopamine as well as other catecho-
lamines inhibit erythrocyte apoptosis by preventing
scramblase activation and subsequent phosphatidylserine
exposure on the cell membrane [37], which in turn trig-
gers the clearance of apoptotic cells by macrophages.
The aforementioned data prompted us to analyze
DDC mRNA expression in HNSCC and adjacent non-
cancerous tissue specimens resected from patients hav-
ing malignant tumors in larynx, pharynx, tongue, buccal
mucosa, parotid glands, or nasal cavity, with the use of
an hypersensitive quantitative real-time PCR (qRT-PCR)
method based on the SYBR Green chemistry, and to
evaluate its clinical significance and application as a
novel tissue biomarker for HNSCC.Methods
Patients’ tissue specimens
A total of 53 malignant tumors and 34 adjacent non-
cancerous tissue specimens from patients having under-
gone surgical treatment for primary HNSCC at Athens
General Hospital “Hippokration” (Athens, Greece) be-
tween 2005 and 2007, were included in the current
study. Tissue specimens were resected from larynx (20
cases), pharynx (5 cases), tongue (14 cases), buccal mu-
cosa (5 cases), parotid glands (5 cases), and nasal cavity
(4 cases). The age of the patients included in this study
varied from 34.0 to 90.0 years, with a mean ± SE of 63.1
± 1.6. All specimens incorporated in the study were
selected after having taken into account the availability
of sufficient tissue mass for RNA extraction and assay,
while they had been frozen in liquid nitrogen immedi-
ately after their resection.
The present study was conducted in accordance
with the ethical standards of the World Medical Associ-
ation Declaration of Helsinki (version: 2008), and was
approved by the institutional review board of Athens Gen-
eral Hospital “Hippokration” (Athens, Greece). Moreover,
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participating in this study.
RNA extraction and reverse transcription
Tissue specimens were pulverized and then dissolved in
TRI Reagent (Ambion Europe Ltd., Huntingdon, UK).
Following the manufacturer’s instructions, total RNA
was extracted and diluted in RNA Storage Solution
(Ambion Europe Ltd.), and stored at -80oC until use.
First-strand cDNA was then synthesized using the M-
MuLV Reverse Transcriptase, RNase H– (Finnzymes Oy,
Vantaa, Finland), RNaseOUT RNase inhibitor (Invitro-
gen, Carlsbad, CA, USA), and oligo(dT)12-18 as primer,
according to the manufacturer’s instructions.
Quantitative real-time PCR (qRT-PCR)
Taking into account the sequences of the DDC and
GAPDH cDNA (GenBank Accession Numbers: NM_000790
and NM_002046, respectively), we designed two pairs of
gene-specific primers. The DDC primers anneal to all
DDC transcripts except for the alt-DDC variant, which
possesses an alternative C-terminus [10], and give birth to
a single amplicon. The sequences of the DDC and
GAPDH real-time PCR primers, the lengths of the PCR
amplicons, and their melting temperatures (Tm) are
shown in Table 1. Quantitative real-time PCR (qRT-PCR)
was accomplished on a 7500 Real Time PCR System (Ap-
plied Biosystems, Foster City, CA, USA) using the SYBR
Green chemistry, and dissociation curves of the PCR pro-
ducts were next produced, as previously described [38],
allowing for the discrimination of the main PCR products
from primer-dimers or other non-specific products. Each
real-time PCR reaction was conducted in duplicate, in
order to evaluate data reproducibility.
Calculations took place with the use of the comparative
Ct (2-ddCt) method [39]. In our study, GAPDH played the
role of an internal control gene for the normalization of
the PCRs for the amount of RNA added to the first-strand
cDNA synthesis reactions, while the colorectal adenocar-
cinoma epithelial cell line Caco-2 served as a calibrator.
ddCt stands for the difference between the mean dCt
value of a HNSCC sample and the mean dCt of the cali-
brator, both calculated after the same PCR run, while dCt
represents the difference between the threshold cycle (Ct)
of the target gene (DDC) and the Ct of the reference gene
(GAPDH) of the same sample. Normalized results wereTable 1 Primers used for real-time PCR amplification of DDC a




50-GGGTCATTGATGGCAACAATATC-30expressed as arbitrary units (a.u.), standing for the ratio of
DDC mRNA copies to 1000 GAPDH mRNA copies calcu-
lated for each specimen, in relation to the same ratio cal-
culated for Caco-2 cells.
Statistical analysis
Advanced biostatistical analysis was carried out only
with regard to the laryngeal squamous cell carcinoma
(LSCC) and tongue squamous cell carcinoma (TSCC)
specimens, since the small number of cases in the rest
HNSCC patients’ groups did not allow an extensive ana-
lysis to be carried out. LSCC and TSCC patients were
classified in subgroups according to the TNM stage, the
histological grade, and the size of their tumors; DDC
mRNA levels in these subgroups were compared using
the non-parametric Mann-Whitney U or Kruskal-Wallis
test, where appropriate.
Results
Validation of the comparative Ct (2-ddCt) method for DDC
mRNA quantification
The validation of the comparative Ct (2-ddCt) method, in
order to be feasible, requires two presuppositions. More
specifically, the PCR amplification efficiencies of the tar-
get and the reference genes should approximate to 100%
and be quite equal to each other [39]. In the present
study, both prerequisites were tested in a validation ex-
periment, in which the Ct values of DDC and GAPDH
cDNA amplification were determined in a dilution series
of Caco-2 cDNA over a 104-fold range and then plotted
against the log cDNA dilution. The Ct values corre-
sponded to the number of cycles at which the fluores-
cence emission monitored in real time reached a
threshold of 10 times the standard deviation of the mean
baseline emission from cycles 3 to 15 (Figure 1A). It
should be added that all PCR products were gene-specific,
as illustrated by the dissociation curves (Figure 1B). The
slopes of DDC and GAPDH amplification plots, as illu-
strated in Figure 1C, are similar (-3.339 and -3.394, re-
spectively). Applying the formula E(%) = [-1 + 10(-1/α)].100,
where E(%) is the real-time PCR efficiency for amplifica-
tion of each gene and α is the slope of the corresponding
amplification plot, the values of the efficiencies of DDC
and GAPDH PCR amplification were 99.3% and 97.1%, re-
spectively. Therefore, both prerequisites for the applica-
tion of the 2-ddCt method were satisfied.nd GAPDH




Figure 1 Relative quantification of DDC mRNA expression in a laryngeal squamous cell carcinoma specimen, using qRT-PCR. (A)
Amplification plots of DDC and GAPDH cDNAs, (B) dissociation curves of the respective amplicons, showing dRn plotted against cycle number,
and (C) validation of the comparative Ct (2-ddCt) method, to evaluate the efficiency of DDC and GAPDH amplification.
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non-cancerous specimens of the head and neck
DDC mRNA expression was lower in LSCC specimens
than in non-malignant counterparts, varying between
0.05 and 164.91 a.u. with a mean±S.E. of 17.50 ± 11.52 a.u.
in the former, while ranging from 0.05 to 359.72 a.u. with
a mean±S.E. of 44.02 ± 25.71 a.u. in the latter (Table 2).
Similarly, DDC mRNA expression levels presented a slight
decrease in TSCC specimens, in comparison with their
non-malignant counterparts. Therefore, DDC mRNA
levels in laryngeal tumors fluctuated between 0.05 and
93.9 a.u. with a mean±SE of 7.43 ± 7.21, whereas in non-
malignant laryngeal tissue specimens they ranged from
0.05 to 128.80 a.u. with a mean±SE of 24.55 ± 16.99
(Table 2).
Table 3 shows features of the distribution of DDC
mRNA expression in tumors resected from pharynx, buc-
cal mucosa, parotid glands, and nasal cavity. Because of
the small number of cases of each group, only descriptive
statistical analysis was performed for these results. Thus,
DDC mRNA levels seem to be lower in tumors of thenasal cavity than in non-cancerous counterparts. In con-
trast, higher levels of DDC transcripts were detected in
malignant neoplasms of pharynx and parotid glands, com-
pared to their non-malignant counterparts.
DDC mRNA expression analysis in subgroups of LSCC and
TSCC patients
LSCC and TSCC groups of patients were further classified
in subgroups, according to classical clinicopathological
parameters, such as tumor size, TNM stage, and histo-
logical grade. DDC mRNA expression analysis was then
conducted for each subgroup, and DDC transcription
levels were compared among distinct patients’ subgroups
using the non-parametric Mann-Whitney U or Kruskal-
Wallis test, as described in the “Methods” section.
Concerning LSCC patients, those bearing small
tumors exhibited remarkably increased levels of DDC
mRNA, in contrast to patients with bigger tumors (p =
0.033). In particular, in patients with tumor size ≤2 cm,
DDC expression showed a mean±S.E. of 40.95 ± 25.88 a.u.,
whereas in patients with tumor size >2 cm the respective
Table 2 DDC mRNA expressiona analysis in patients with laryngeal or tongue tumors and their non-cancerous
counterparts
Variable Mean ± SEb Range Percentiles
10 25 50 75 90
Median
DDC in laryngeal tumors (N = 19) 17.50 ± 11.52 0.05 – 164.91 0.05 0.05 0.05 0.52 153.89
DDC in non-cancerous laryngeal tissues (N = 14) 44.02 ± 25.71 0.05 – 359.72 0.05 0.05 3.71 61.61 228.09
DDC in tongue tumors (N = 13) 7.43 ± 7.21 0.05 – 93.9 0.05 0.05 0.05 0.63 56.77
DDC in non-cancerous tongue tissues (N = 8) 24.55 ± 16.99 0.05 – 128.80 0.05 0.05 0.05 49.92 128.80
a a.u.: arbitrary units.
b Standard error of the mean.
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being at an early disease stage (TNM stage I) dis-
played, also, very elevated DDC expression, in com-
parison with patients diagnosed at an intermediate
(TNM stage II) or an advanced stage (TNM stage III)
(p = 0.027). On the other hand, no statistically signifi-
cant difference was noticed between subgroups of
TSCC patients classified according to the histological
grade of the tumor.
Similarly, DDC mRNA expression was found to be
2.7-fold higher in tongue tumors of ≤2 cm than in bigger
tumors (p = 0.028). A dramatic decrease in DDC gene
transcription was also detected in intermediate- and
late-stage TSCC patients (p = 0.025). In more detail, in
patients with TNM stage I tongue SCC, DDC expression
had a mean±S.E. of 31.73 ± 3.11 a.u., while in patients
with tongue SCC of TNM stage II and III the mean±S.E.
was 0.18 ± 0.13 and 0.05 ± 0.003, respectively (Table 5).
No statistically significant differences were observed be-
tween subgroups of TSCC patients classified according
to the tumor histological grade.
Discussion
HNSCC today represents the sixth most common malig-
nancy affecting people in the developed countries, while
the largest proportion of the cases arise in the areas of lar-
ynx and the oral cavity [1]. The leading cause of the
HNSCC is predominately tobacco and alcohol abuse.
Other factors which enhance the possibility of developingTable 3 Distribution of DDC mRNA expressiona in head and n
counterparts
Tissue Cancerous samples
Mean ± SEb Median Ran
Pharynx 5.51 ± 4.66 0.20 0.05 –
Buccal mucosa 2.71 ± 2.66 0.05 0.05 –
Parotid glands 2.23 ± 1.88 0.10 0.05 –
Nasal cavity 0.39 ± 0.24 0.23 0.05 –
a a.u.: arbitrary units.
b Standard error of the mean.such tumors are the family history of the disease, which is
indicative of genetic predisposition, virus infections such
as HPV (human papillomavirus), EBV (Epstein-Barr virus),
HSV (Herpes simplex virus) and HIV (human immuno-
deficiency virus), as well as an unhealthy diet and exposure
to carcinogens on a permanent base, e.g. an unsanitary
professional environment [3].
Undoubtedly, 5-year survival rates of advanced laryn-
geal and pharyngeal carcinoma patients have improved a
lot during the last decade, mostly thanks to the novel
therapeutic approaches that have emerged; still, the
overall survival (OS) of HNSCC patients remains among
the lowest. Usually, treatment strategies fail or procure
rather modest improvement and consequently, locore-
gional recurrence, distant metastases, and second pri-
mary tumors are frequent. In particular, positive nodal
status is considered as the most adverse independent
prognosticator in HNSCC [7]. Despite the recent
advances, the morbidity and the mortality attributed to
this disease remain among the highest [2]. The poor
prognosis of HNSCC patients is mostly due to lack of
established biomarkers for early detection and treatment
monitoring [40]. Taking all this information into consid-
eration, the discovery of novel, reliable molecular bio-
markers for HNSCC may contribute to the prolongation
of patients’ survival through early diagnosis, reliable
prognosis and/or effective treatment response monitor-
ing, while it may also illuminate the molecular back-
ground of this cancer type [41].eck squamous cell carcinomas and in non-cancerous
Non-cancerous samples
ge Mean ± SEb Median Range
23.98 4.21 ± 3.5 1.07 0.05 – 14.65
13.33 - - -
9.69 0.31 ± 0.26 0.05 0.05 – 1.07
1.05 8.75 ± 8.69 0.05 0.05 – 26.13
Table 4 DDC mRNA expressiona analysis in subgroups of
LSCC patients, classified according to classical
clinicopathological parameters
Variable No. of patients Mean ± SEb Median p value
Tumor size
≤ 2 cm 8 40.95 ± 25.88 0.41 0.033c
> 2 cm 11 0.42 ± 0.37 0.05
TNM stage
I 5 63.94 ± 39.01 0.52 0.027d
II 3 2.65 ± 2.61 0.05
III 11 0.42 ± 0.37 0.05
Histological grade
I 7 0.12 ± 0.07 0.05 0.46d
II 6 28.22 ± 27.35 0.05
III 6 27.03 ± 25.40 0.17
a a.u.: arbitrary units.
b Standard error of the mean.
c Calculated using the Mann-Whitney U test.
d Calculated using the Kruskal-Wallis test.
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proposed as potential biomarkers in HNSCC, including
EGFR, cyclin D1 (CCND1), Ki67 antigen, FAS, FASL,
BCL2, BCL2L12, TP53, P27, vascular endothelial growth
factor (VEGF), matrix metallopeptidases (MMPs), and
kallikrein-related peptidases (KLKs) [7,42-46]. Our study
introduces the mRNA expression of DDC as a new
promising tumor biomarker for HNSCC. DDC mRNA
expression has already been demonstrated to increase in
many tissues; modulations in its expression levels have
been reported in various malignancies, such as neuro-
blastoma [30], small cell lung carcinoma [16], andTable 5 DDC mRNA expressiona analysis in subgroups of
TSCC patients, classified according to classical
clinicopathological parameters
Variable No. of patients Mean ± SEb Median p value
Tumor size
≤ 2 cm 7 13.76 ± 3.36 0.26 0.028c
> 2 cm 6 5.08 ± 0.02 0.05
TNM stage
I 3 31.73 ± 3.11 1.00 0.025d
II 7 0.18 ± 0.13 0.05
III 3 0.05 ± 0.003 0.05
Histological grade
I 5 0.24 ± 0.19 0.05 0.097d
II 4 0.28 ± 0.23 0.05
III 3 31.34 ± 31.29 0.05
a a.u.: arbitrary units.
b Standard error of the mean.
c Calculated using the Mann-Whitney U test.
d Calculated using the Kruskal-Wallis test.prostate cancer [20,31]. Most interestingly, strong DDC
mRNA expression has been detected in tumors of the
gastrointestinal tract [33,38].
Extremely high DDC activity in neoplastic cells is a
hallmark of several peripheral cancers. This is mostly ap-
parent in lung tumors of small-cell origin, although non-
sense alternatively spliced variants are also present [35].
Furthermore, a remarkable increase in DDC activity has
been detected in primary intestinal cancer as well as in
its related metastases in the spleen and liver, in compari-
son with normal tissue [25]. The significance of elevated
DDC activity and increased monoamine synthesis by the
neoplastic cells remains to be elucidated [35]; still, it is
closely related to the involvement of DDC in cancer.
In this study, we undertook the quantitative expression
analysis of DDC mRNA in SCCs of the larynx, pharynx,
tongue, buccal mucosa, parotid glands, and nasal cavity,
as well as in adjacent non-cancerous counterparts. Our
results revealed that DDC mRNA levels are 2.5- and 3.3-
fold lower in laryngeal and tongue tumors, respectively,
than in non-cancerous adjacent tissues. Moreover, DDC
mRNA expression differs significantly in LSCC and
TSCC patients, when classified according to the TNM
stage or size of malignant tumors. Concretely, LSCC
patients bearing tumors of early TNM stage and/or
smaller than 2 cm displayed higher DDC mRNA expres-
sion than patients with more advanced tumors. The
decreased DDC mRNA expression that seems to be
associated with progression of HNSCC could imply a
protective role of DDC against HNSCC, perhaps owing
to its indirect association with apoptosis [37]. In spite of
the fact that clinical comorbidities have been shown to
significantly affect survival over TNM prognosticators
[47], the TNM classification consistently correlates with
DFS and OS [48]. Given that the TNM staging of LSCC
remains the most significant predictor of survival and
that DDC mRNA levels are high in early-stage patients,
DDC could constitute a favorable prognostic indicator in
LSCC. Moreover, DDC has a similar expression pattern
in colorectal adenocarcinoma, possessing favorable prog-
nostic value. Elevated DDC mRNA expression levels
were found in well-differentiated and early-stage colo-
rectal adenocarcinomas, and were shown to predict bet-
ter patient outcome, in terms of DFS and OS [38]. The
prognostic potential of DDC mRNA status in prostate
cancer has also recently been uncovered. In more detail,
DDC mRNA is likely to constitute an unfavorable prog-
nosticator in this malignancy, predicting biochemical re-
currence and poor DFS in prostate cancer patients
treated by radical prostatectomy [32]. Additionally, DDC
mRNA levels were shown to be significantly higher in
prostate cancer than in benign prostate hyperplasia
patients. Therefore, DDC mRNA status seems to possess
significant discriminatory value in this malignancy [31].
Geomela et al. BMC Cancer 2012, 12:484 Page 7 of 9
http://www.biomedcentral.com/1471-2407/12/484On the other hand, increased DDC expression is asso-
ciated with peritoneal metastasis, since its mRNA is
upregulated in gastric cancer peritoneal dissemination
[33]. This discrepancy could be attributed to the
utilization of distinct gene promoters [49], which regu-
late the expression of this gene in a tissue-specific man-
ner [50]. In fact, several molecules have been shown to
be overexpressed in various malignancies, while being
downregulated in other types of cancer. For instance,
BCL2L12, a member of the BCL2 family of apoptosis-
related genes, is overexpressed in undifferentiated naso-
pharyngeal carcinoma [43] and in poorly differentiated
TSCC, whereas its mRNA levels are lower in LSCC of
advanced TNM stage, compared to early-stage laryngeal
tumors [45].
In this framework, the potential correlation between
DDC mRNA expression and DFS and/or OS of LSCC
patients deserves further investigation. Hence, our future
goals include DDC mRNA expression analysis in larger
cohorts of LSCC and TSCC samples in order to validate
the current results, since the number of SCC specimens
used in this study constitutes a limiting factor, owing to
the fact that HNSCC is not a very common cancer type
in Greece [51]. Furthermore, the statistically significant
correlation of DDC expression with the tumor size and
the TNM stage of the disease, as confirmed in LSCC
and TSCC patients, might contribute to more accurate
and effective staging of laryngeal and tongue tumors, re-
spectively. The implementation of molecular criteria in
disease staging may aid to distinguish between neo-
plasms which, though different at the molecular level,
are grouped together, based on the current morpho-
logical and clinicopathological parameters. To sum up,
this study proposes DDC mRNA expression as a useful
biomarker for better classification of the laryngeal and
tongue tumors. Although mRNA levels are heavily
dependent on ribonuclease activity, DDC mRNA expres-
sion, if combined with other putative biomarkers, could
add to their prognostic value or be part of a multipara-
metric model significantly assisting with HNSCC classifi-
cation, prognosis, and response to chemotherapy.
Conclusion
To the best of our knowledge, this is the first time that
this gene is studied in HNSCC. Our results imply the
clinical usefulness of DDC mRNA expression as a poten-
tial prognostic biomarker in TSCC and/or LSCC, which
principally compose the vast majority of HNSCC cases.
Additional studies could shed light to the molecular
mechanisms underlying the role of DDC in HNSCC pro-
gression, and thoroughly examine the prognostic value
of DDC mRNA expression in LSCC, TSCC, and other
types of HNSCC. With regard to our future goals, we
are planning to compare the DDC mRNA expressionprofile in a larger cohort of LSCC and TSCC patients,
and in healthy controls. The expression analysis will also
discriminate between distinct variants of the DDC gene.
Furthermore, we intend to assess the prognostic value of
this potential biomarker in HNSCC and to examine the
effect of widely used chemotherapy on DDC expression.
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